Articles published by Beam Therapeutics
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
February 27, 2024
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
January 08, 2024
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
December 14, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 08, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
September 05, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
August 08, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 11, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
February 28, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
February 07, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
January 09, 2023
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
December 02, 2022
From Beam Therapeutics
Via GlobeNewswire
Tickers
BEAM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.